Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma

Inclusion Criteria: * Age ≥18 years. * Radiographically suspected or confirmed high-grade glioma planned for surgical resection as part of standard clinical care. * Able to start disulfiram at least 3 days prior to planned surgery (treatment window 3-14 days pre-op). * In-patient status for the duration of study. * Karnofsky Performance Status (KPS) ≥70%. * Adequate organ function within 14 days prior to first dose: * ANC ≥1.5 x 10\^9/L * Platelets ≥100 x 10\^9/L * Hemoglobin ≥9 g/dL * AST/ALT ≤2.5 x ULN * Total bilirubin ≤1.5 x ULN (unless Gilbert syndrome, in which case \<5 x ULN). * Total bilirubin ≤1.5 x ULN (unless Gilbert syndrome, in which case \<5 x ULN). * Ability to understand and willingness to sign written informed consent. * Willingness to avoid alcohol and alcohol-containing products during treatment and for 14 days after last dose. Exclusion Criteria: * Any dexamethasone (or other systemic glucocorticoid for cerebral edema) administered prior to enrollment/first dose (including outpatient or ED administration). This does not include inhalers or topical steroids. * Imaging features that are atypical for high-grade glioma that have reasonable concern for competing differential diagnoses (e.g. PCNSL, tumefactive MS, etc.) * Known hypersensitivity to disulfiram or thiuram derivatives. * Active or severe hepatic disease (e.g. hepatitis, cirrhosis, known liver disease that may be exacerbated by disulfiram), or baseline liver tests above inclusion thresh…